

Mankind partners with BDR for distribution of COVID-19 drug Baricitinib

24 June 2021 | News

Under the trademark BARIKIND



Mankind Pharma partners with BDR Pharmaceuticals International for distributing the COVID-19 drug Baricitinib under the trademark BARIKIND that received restricted emergency use approval, for use in combination with remdesivir.

According to the partnership, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary license from Eli Lilly and Company and Mankind Pharma will be distributing the same.

Baricitinib received restricted emergency use approval, for use in combination with remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Lilly received permission for restricted emergency use from Central Drugs Standard Control Organization, a division of Ministry of Health.